A phase I report described durable peritoneal disease control in three patients with advanced gastric cancer and peritoneal metastasis treated with satri-cel, a claudin 18.2-targeted CAR-T therapy. All three had confirmed high CLDN18.2 expression and experienced verified clinical and radiologic benefit after infusion. The cases included one patient who underwent conversion surgery after eight months and later resection of ovarian metastases with no further progression reported, alongside two other patients with overall survival durations of 44 and 35 months. The report also described a divergence between peripheral CAR-T clearance and local tissue persistence. For teams targeting peritoneal spread, the finding is notable because durable local control has historically been difficult with systemic approaches, and it adds clinical texture to ongoing CLDN18.2 cell-therapy development.